Head to Head Comparison: Genenta Science (NASDAQ:GNTA) vs. Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Dyadic International and Genenta Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-188.09%	-149.16%	-59.81%
Genenta Science	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Dyadic International and Genenta Science, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	0	0	1	0	3.00
Genenta Science	0	0	1	0	3.00

Dyadic International presently has a consensus price target of $6.00, indicating a potential upside of 220.86%. Genenta Science has a consensus price target of $25.00, indicating a potential upside of 364.68%. Given Genenta Science’s higher probable upside, analysts plainly believe Genenta Science is more favorable than Dyadic International.

Risk & Volatility

Dyadic International has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Insider & Institutional Ownership

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 28.8% of Dyadic International shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Dyadic International and Genenta Science”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$2.90 million	19.08	-$6.80 million	($0.23)	-8.13
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A

Dyadic International has higher revenue and earnings than Genenta Science.

Summary

Genenta Science beats Dyadic International on 6 of the 9 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.